SFRP1 and breast neoplasm: This was supported by the finding that the extracellular inhibitor of Wnt/β-catenin pathway expression named secreted frizzled-related protein 1 (SFRP1) is significantly downregulated in many breast tumors and this is related to poor prognosis as well as therapy resistance33.